The Coalition for Epidemic Preparedness Innovations (CEPI) has allocated approximately $60 million to Moderna and two other research groups to accelerate the development of vaccines against Ebola Bundibugyo (BDBV). This funding comes as BDBV, a deadly strain of the virus, continues to spread through eastern Democratic Republic of Congo (DRC) and has spread to Uganda, prompting global health agencies to declare a public health emergency.
CEPI, a key player in global health security and an early investor in COVID-19 vaccine development, aims to have BDBV vaccines ready for clinical trials within months. Dr. Richard Hatchett, CEO of CEPI, announced the funding on Monday, emphasizing the urgency to develop countermeasures for the current outbreak, which has resulted in hundreds of confirmed cases and dozens of deaths.
Context of the Ebola Bundibugyo Outbreak
The current outbreak of Ebola Bundibugyo in the eastern DRC is a serious public health concern. According to the Africa Centres for Disease Control and Prevention and the World Health Organization (WHO), there have been 282 confirmed cases and 42 deaths in the DRC, with an additional 1,100 suspected cases. Nine confirmed cases, including one death, have also been reported in Uganda.
Ebola Bundibugyo Virus (BDBV) is a distinct strain of the Ebola virus. Unlike the more common Zaire strain, for which an approved vaccine (Ervebo by Merck) exists, there are currently no approved vaccines or treatments specifically for BDBV. This lack of existing medical countermeasures makes the current situation particularly challenging.
Accelerated Vaccine Development Efforts
CEPI’s significant investment targets three promising vaccine candidates. Moderna will receive up to $50 million to support the preclinical and early clinical development of its investigational BDBV vaccine. This funding will also cover manufacturing and progression into later-stage trials, contingent on positive early data.
Moderna’s CEO, Stephane Bancel, expressed optimism, stating that their preclinical work has shown promising results. The company aims to develop a vaccine that not only prevents disease but also simplifies dosing, though it remains to be determined if a one or two-dose regimen will be most effective. Phase 1 trials will be crucial in answering these questions before larger trials are conducted in Africa.
Beyond Moderna, CEPI is investing up to $8.6 million in a vaccine candidate developed by the University of Oxford and manufactured by the Serum Institute of India. This vaccine utilizes the same viral vector technology as the Oxford/AstraZeneca COVID-19 vaccine.
Additionally, an initial $3.2 million is allocated to the International AIDS Vaccine Initiative (IAVI) for its single-dose BDBV vaccine candidate. This candidate employs the same technology as Merck’s Ervebo vaccine, which is approved for the Zaire strain, and has demonstrated survival benefits in animal studies.
Challenges and Support for the Response
While vaccine development is a critical focus, challenges remain. Dr. Hatchett noted that the security situation in eastern Congo could complicate clinical trials. Furthermore, the logistical and financial aspects of future vaccine rollout are already being considered.
The question of who will fund and manage the purchase and distribution of these potential vaccines is paramount. Dr. Hatchett stressed the need for these conversations to begin now, even as vaccines are still in development. The WHO’s role in sponsoring or conducting future trials is also under discussion, with IAVI CEO Mark Feinberg indicating that the WHO may not assume the same level of responsibility as in past outbreaks.
Beyond CEPI’s funding for vaccine development, other global health organizations are bolstering the broader Ebola response. The Gavi vaccine alliance has committed up to $50 million, and the World Bank’s Pandemic Fund announced grants totaling up to $220.6 million to support response efforts.
Implications and Future Outlook
The swift allocation of funds by CEPI signals a proactive approach to a rapidly evolving public health crisis. The success of these accelerated development programs could mean that effective BDBV vaccines become available much sooner than previously anticipated for such a novel threat.
For the affected regions, the prospect of approved vaccines offers hope in controlling the current outbreak and preventing future ones. However, the challenges of conducting trials in insecure areas and ensuring equitable access to vaccines once developed will require significant international cooperation and sustained funding.
The speed at which Oxford and Serum were able to prepare trial doses for a different outbreak last year, around six weeks, offers a benchmark for what might be achievable. If similar timelines can be met for BDBV vaccines, it would mark a significant advancement in rapid pandemic preparedness. The focus will now shift to the successful completion of early-stage trials and the complex planning required for a global health response.
Leave a Reply